mesa lab - MLAB

MLAB

Close Chg Chg %
123.74 1.23 0.99%

Open Market

124.97

+1.23 (0.99%)

Volume: 47.40K

Last Updated:

Sep 9, 2026, 11:46 AM EDT

Company Overview: mesa lab - MLAB

MLAB Key Data

Open

$124.00

Day Range

123.24 - 126.08

52 Week Range

58.83 - 132.69

Market Cap

$715.04M

Shares Outstanding

5.60M

Public Float

5.36M

Beta

0.97

Rev. Per Employee

N/A

P/E Ratio

151.18

EPS

$0.86

Yield

51.72%

Dividend

$0.16

EX-DIVIDEND DATE

Aug 31, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

168.54K

 

MLAB Performance

1 Week
 
-3.16%
 
1 Month
 
20.55%
 
3 Months
 
17.31%
 
1 Year
 
100.68%
 
5 Years
 
-53.83%
 

MLAB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About mesa lab - MLAB

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

MLAB At a Glance

Mesa Laboratories, Inc.
12100 West 6th Avenue
Lakewood, Colorado 80228
Phone 1-303-987-8000 Revenue 249.13M
Industry Medical Specialties Net Income 6.71M
Sector Health Technology 2026 Sales Growth 3.383%
Fiscal Year-end 03 / 2027 Employees 717
View SEC Filings

MLAB Valuation

P/E Current 151.183
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 73.311
Price to Sales Ratio 1.975
Price to Book Ratio 2.623
Price to Cash Flow Ratio 11.49
Enterprise Value to EBITDA 15.173
Enterprise Value to Sales 2.545
Total Debt to Enterprise Value 0.266

MLAB Efficiency

Revenue/Employee 347,461.646
Income Per Employee 9,361.227
Receivables Turnover 5.649
Total Asset Turnover 0.579

MLAB Liquidity

Current Ratio 1.717
Quick Ratio 1.291
Cash Ratio 0.435

MLAB Profitability

Gross Margin 56.563
Operating Margin 7.43
Pretax Margin 4.822
Net Margin 2.694
Return on Assets 1.559
Return on Equity 3.879
Return on Total Capital 1.89
Return on Invested Capital 2.257

MLAB Capital Structure

Total Debt to Total Equity 90.65
Total Debt to Total Capital 47.548
Total Debt to Total Assets 39.47
Long-Term Debt to Equity 85.65
Long-Term Debt to Total Capital 44.925
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Mesa Lab - MLAB

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
219.08M 216.19M 240.98M 249.13M
Sales Growth
+18.85% -1.32% +11.47% +3.38%
Cost of Goods Sold (COGS) incl D&A
108.56M 105.43M 108.83M 108.22M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
33.13M 31.57M 24.53M 23.27M
Depreciation
4.31M 4.23M 5.38M 5.25M
Amortization of Intangibles
28.82M 27.34M 19.14M 18.02M
COGS Growth
+12.41% -2.89% +3.23% -0.57%
Gross Income
110.52M 110.76M 132.14M 140.91M
Gross Income Growth
+25.94% +0.22% +19.31% +6.64%
Gross Profit Margin
+50.45% +51.23% +54.84% +56.56%
2023 2024 2025 2026 5-year trend
SG&A Expense
107.20M 106.07M 115.81M 124.55M
Research & Development
20.49M 19.30M 19.52M 20.31M
Other SG&A
86.71M 86.77M 96.29M 104.24M
SGA Growth
+31.03% -1.06% +9.18% +7.54%
Other Operating Expense
- - - (2.14M)
-
Unusual Expense
- - 276.77M (2.89M)
-
EBIT after Unusual Expense
3.32M (272.07M) 19.22M 18.51M
Non Operating Income/Expense
1.06M 2.12M (1.40M) 4.20M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.77M 5.70M 11.86M 10.69M
Interest Expense Growth
+22.78% +19.43% +108.16% -9.84%
Gross Interest Expense
4.77M 5.70M 11.86M 10.69M
Interest Capitalized
- - - -
-
Pretax Income
(389.00K) (275.65M) 5.96M 12.01M
Pretax Income Growth
-110.88% -70,760.67% +102.16% +101.54%
Pretax Margin
-0.18% -127.50% +2.47% +4.82%
Income Tax
(1.32M) (21.40M) 7.93M 5.30M
Income Tax - Current - Domestic
1.13M 4.68M 5.21M 1.25M
Income Tax - Current - Foreign
1.07M 2.33M 2.79M 5.33M
Income Tax - Deferred - Domestic
(1.64M) (22.24M) 76.00K 1.89M
Income Tax - Deferred - Foreign
(1.88M) (6.17M) (137.00K) (3.17M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
930.00K (254.25M) (1.97M) 6.71M
Minority Interest Expense
- - - -
-
Net Income
930.00K (254.25M) (1.97M) 6.71M
Net Income Growth
-50.29% -27,438.28% +99.22% +440.02%
Net Margin Growth
+0.42% -117.60% -0.82% +2.69%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
930.00K (254.25M) (1.97M) 6.71M
Preferred Dividends
- - - -
-
Net Income Available to Common
930.00K (254.25M) (1.97M) 6.71M
EPS (Basic)
0.1748 -47.205 -0.3641 1.2173
EPS (Basic) Growth
-51.31% -27,105.15% +99.23% +434.33%
Basic Shares Outstanding
5.32M 5.39M 5.42M 5.51M
EPS (Diluted)
0.1735 -47.205 -0.3641 1.2061
EPS (Diluted) Growth
-50.53% -27,307.49% +99.23% +431.26%
Diluted Shares Outstanding
5.36M 5.39M 5.42M 5.57M
EBITDA
36.45M 36.27M 40.86M 41.78M
EBITDA Growth
+17.54% -0.51% +12.67% +2.25%
EBITDA Margin
+16.64% +16.78% +16.96% +16.77%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 109.50
Number of Ratings 3 Current Quarters Estimate 1.593
FY Report Date 09 / 2026 Current Year's Estimate 7.583
Last Quarter’s Earnings 2.68 Median PE on CY Estimate N/A
Year Ago Earnings 11.41 Next Fiscal Year Estimate 8.747
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate 1.59 2.08 7.58 8.75
High Estimates 2.34 2.82 10.43 11.50
Low Estimate 0.20 0.71 2.37 4.47
Coefficient of Variance 75.80 57.10 59.62 42.92

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Mesa Lab - MLAB

Date Name Shares Transaction Value
Aug 18, 2026 R. Tony Tripeny Director 6,298 Open market or private purchase of non-derivative security Non-derivative transaction at $113.69 per share 716,019.62
Mar 11, 2026 Mark Christopher Capone Director 3,429 Open market or private purchase of non-derivative security Non-derivative transaction at $76.35 per share 261,804.15
Mar 11, 2026 Shiraz S. Ladiwala Director 8,523 Open market or private purchase of non-derivative security Non-derivative transaction at $72.23 per share 615,616.29
Oct 29, 2025 Gary M. Owens President and CEO 64,135 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Mesa Lab in the News